These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30297597)

  • 21. C-reactive protein and myocardial infarction during percutaneous coronary intervention.
    Saleh N; Svane B; Velander M; Nilsson T; Hansson LO; Tornvall P
    J Intern Med; 2004 Jan; 255(1):33-9. PubMed ID: 14687236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention.
    Bressi E; Mangiacapra F; Ricottini E; Cavallari I; Colaiori I; Di Gioia G; Creta A; Di Sciascio G
    Am J Cardiol; 2016 Oct; 118(7):980-4. PubMed ID: 27515894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the incidence of periprocedural myocardial infarction between percutaneous coronary intervention with versus without rotational atherectomy using propensity score-matching.
    Mizuno Y; Sakakura K; Jinnouchi H; Taniguchi Y; Tsukui T; Yamamoto K; Seguchi M; Wada H; Fujita H
    Sci Rep; 2021 May; 11(1):11140. PubMed ID: 34045490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Value of Aortic Valve Calcification for Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention.
    Shibata Y; Ishii H; Suzuki S; Tanaka A; Tatami Y; Harata S; Ota T; Shimbo Y; Takayama Y; Kunimura A; Hirayama K; Harada K; Osugi N; Murohara T
    J Atheroscler Thromb; 2017 May; 24(5):487-494. PubMed ID: 27733732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Free fatty acids as a marker for predicting periprocedural myocardial injury after coronary intervention.
    Wang Y; Zhang HW; Guo YL; Zhu CG; Wu NQ; Li JJ
    Postgrad Med J; 2019 Jan; 95(1119):18-22. PubMed ID: 30700582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting.
    Verdoia M; Schaffer A; Barbieri L; Cassetti E; Di Giovine G; Marino P; De Luca G;
    J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):100-5. PubMed ID: 24625566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.
    Liu Y; Tan N; Zhou YL; Chen YY; Chen JY; Chen J; Luo JF
    J Nephrol; 2012; 25(3):332-40. PubMed ID: 21928234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes.
    Zeng RX; Li XL; Zhang MZ; Guo YL; Zhu CG; Guo LH; Li S; Zhang Y; Li JJ
    Atherosclerosis; 2014 Dec; 237(2):536-43. PubMed ID: 25463086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents.
    Tandjung K; Basalus MW; Muurman E; Louwerenburg HW; van Houwelingen KG; Stoel MG; de Man FH; Jansen H; Huisman J; Linssen GC; Droste HT; Nienhuis MB; von Birgelen C
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):524-30. PubMed ID: 22109857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent.
    Kawamoto H; Panoulas VF; Sato K; Miyazaki T; Naganuma T; Sticchi A; Figini F; Latib A; Chieffo A; Carlino M; Montorfano M; Colombo A
    JACC Cardiovasc Interv; 2015 Jun; 8(7):900-9. PubMed ID: 26003020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Periprocedural myocardial infarction is associated with increased mortality in patients with coronary artery bifurcation lesions after implantation of a drug-eluting stent.
    Chen SL; Zhang JJ; Ye F; Tian NL; Sheiban I; Jepson N; Paiboon C; Sansoto T; Kwan TW; Wen SY; Wang HC; Jiang TM; Wang Y; Chen LL; Qiu CG; Zhang YJ; Chen MX; De Maria A
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():696-705. PubMed ID: 25631678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent.
    Karha J; Bavry AA; Rajagopal V; Henderson MR; Ellis SG; Brener SJ
    Am J Cardiol; 2006 Sep; 98(5):616-8. PubMed ID: 16923447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention.
    Harada K; Kikuchi R; Suzuki S; Tanaka A; Aoki T; Iwakawa N; Kojima H; Hirayama K; Mitsuda T; Sumi T; Negishi Y; Ishii H; Murohara T
    Lipids Health Dis; 2018 Feb; 17(1):21. PubMed ID: 29391013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of angiotensin converting enzyme inhibitors on periprocedural myocardial infarction in patients with metabolic syndrome.
    Ozcan OU; Ustun EE; Gulec S; Gerede DM; Goksuluk H; Vurgun VK; Kaya CT; Erol C
    Cardiol J; 2015; 22(3):323-9. PubMed ID: 25563711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycosylated hemoglobin and the risk of periprocedural myocardial infarction in non-diabetic patients.
    Verdoia M; Schaffer A; Barbieri L; Di Giovine G; Marino P; Suryapranata H; De Luca G;
    J Diabetes Complications; 2015; 29(4):517-22. PubMed ID: 25736187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periprocedural Myocardial Injury After Recanalization of Single Chronic Coronary Occlusion - A Propensity Score Analysis Comparing Long-Term Clinical Outcomes.
    Jaguszewski M; Gilis-Malinowska N; Gutierrez-Chico JL; Chmielecki M; Skarzynski P; Burakowski S; Drewla P; Targonski R; Lewicki L; Dubaniewicz W; Fijalkowski M; Gruchala M; Ciecwierz D
    J Invasive Cardiol; 2017 Feb; 29(2):63-67. PubMed ID: 27845873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization.
    Verdoia M; Barbieri L; Schaffer A; Cassetti E; Marino P; Bellomo G; Sinigaglia F; De Luca G;
    Heart Vessels; 2015 Jan; 30(1):20-7. PubMed ID: 24297745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of dynamic cardiac troponin I concentrations and C-reactive protein in the monitoring of myocardial infarction in patients with repeated myocardial infarction].
    Plak M; Orliński L; Łobos M; Ciesielczyk M; Wlazeł RN; Paradowski MT
    Pol Merkur Lekarski; 2010 Jun; 28(168):444-9. PubMed ID: 20642101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remnant cholesterol predicts periprocedural myocardial injury following percutaneous coronary intervention in poorly-controlled type 2 diabetes.
    Zeng RX; Li S; Zhang MZ; Li XL; Zhu CG; Guo YL; Zhang Y; Li JJ
    J Cardiol; 2017 Aug; 70(2):113-120. PubMed ID: 28209463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Serum Uric Acid, Bilirubin, and C-Reactive Protein as Prognostic Biomarkers of In-Hospital MACE Between Women and Men With ST-Segment Elevation Myocardial Infarction.
    Baumann S; Huseynov A; Koepp J; Jabbour C; Behnes M; Becher T; Renker M; Lang S; Borggrefe M; Lehmann R; Akin I
    Angiology; 2016 Mar; 67(3):272-80. PubMed ID: 26032849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.